Opko Pharmaceuticals LLC, of Miami, gained FDA orphan status for oligonucleotide-based Antagonat (CUR-1916) for the treatment of Dravet syndrome. The Antagonat technology, part of Curna Pharmaceuticals, acquired by Opko in 2011 for $10 million. It was further developed in Opko's Miami research laboratories. (See BioWorld Today, Feb. 2, 2011.)